Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1.2 puts on active option volume of 198K contracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Hims and Hers (HIMS) PT Raised to $61 at Needham
February 25, 2025 6:07 AM ESTNeedham analyst Ryan MacDonald raised the price target on Hims and Hers (NYSE: HIMS) to $61.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "We reiterate our Buy rating & raise our PT to $61 on HIMS following the company's strong 4Q... More
Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)
February 25, 2025 5:36 AM ESTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating and $24.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line: Fundamentally, HIMS' 4Q'24 results were slightly below what we think were buyside expectations. HIMS beat our/consensus revenue by ~1.2%/~2.2%,... More
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
February 25, 2025 5:34 AM ESTTruist Securities analyst Jailendra Singh reiterated a Hold rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "Bottom Line. HIMS posted 4Q24 results with revenues slightly ahead of consensus and adjusted EBITDA in-line. However, compared to the broader investor expectations, results were below. Interestingly, the majority of beat in the quarter (relative to our estimate)... More
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21
February 25, 2025 5:17 AM ESTBofA Securities analyst Michael Cherny reiterated an Underperform rating and $21.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "HIMS 2025 revenue growth guidance embeds a significant level of optimism around two key items: 1) core revenue growth (ex-GLP-1s); and 2) a successful handoff between semaglutide and oral/liraglutide subscriptions into the second half of the... More
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
February 21, 2025 12:23 PM ESTPiper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More
